Noubar Afeyan
| Noubar Afeyan | |
|---|---|
| Born | July 25, 1962 |
| Alma mater |
McGill University Massachusetts Institute of Technology |
| Occupation | Venture capitalist, Entrepreneur, Flagship Ventures |
Noubar Afeyan (born July 25, 1962), is an American entrepreneur, venture capitalist, inventor, technologist, and CEO. In 2000, Afeyan founded Flagship Pioneering to create and fund early-stage start-ups addressing unmet needs in healthcare and sustainability. He is a Senior Lecturer at the MIT Sloan School of Management. He lectures in the United States and internationally on topics ranging from entrepreneurship, innovation and venture capital to biological engineering, drug discovery, medical technologies and renewable energy.
Afeyan is of Armenian heritage and was born in Beirut, Lebanon. His family moved to Montreal, Canada in 1976. Afeyan graduated from McGill University with a BS in Chemical Engineering in 1983. He earned his PhD in Biochemical Engineering from the Massachusetts Institute of Technology in 1987.
In 1988, Afeyan founded PerSeptive Biosystems in Cambridge, MA. While CEO of PerSeptive, Afeyan co-founded and funded numerous other biotechnology companies, including: ChemGenics Pharmaceuticals, acquired by Millennium Pharmaceuticals in 1997; Exact Sciences (NASDAQ:EXAS), Agenus (NASDAQ:AGEN); and Color Kinetics, acquired by Philips 2007. After PerSeptive's acquisition by Perkin Elmer/Applera Corporation in 1998, he became Senior Vice President and Chief Business Officer of Applera, where he initiated and oversaw the creation of Celera Genomics.
In 2000, Afeyan founded Flagship Ventures (renamed Flagship Pioneering in 2016), where he currently serves as Senior Managing Partner and CEO. Flagship Pioneering focuses on creating and investing in first-in-category, high-value life science companies in three principal business sectors: therapeutics, health technologies and sustainability. The company creates companies through a systemic model of entrepreneurial science. Flagship's team of scientists poses scientific hypotheses, works to finesse them, and conducts proof-of-concept experiments that eventually lead to new scientific IP and companies with disruptive potential. Since 2000 this process has led to the launch of around 40 companies. The firm also works with external academic innovations and, in some cases, with early-stage companies looking to partner.
...
Wikipedia